New Test Helps Identify Glioblastoma Patients Who Could Benefit from Bevacizumab
Glioblastomas that express low levels of genes associated with
mesenchymal cells may be more sensitive than other glioblastomas to
bevacizumab, according to a recent study.
In a correlative analysis done as part of a phase III clinical trial,
researchers led by Erik Sulman, M.D., Ph.D., an assistant professor in
the Department of Radiation Oncology at The University of Texas MD
Anderson Cancer Center, sought to identify potential molecular markers
for bevacizumab sensitivity in glioblastoma.
Glioblastoma is one of the most common and difficult to treat brain
tumors. It is often very aggressive and has a high risk of recurrence,
but the mechanisms of glioblastoma tumorigenesis and recurrence are
still poorly understood. Consequently, despite much effort, the
treatment options for these tumors remain limited.
Bevacizumab specifically targets vascular endothelial growth factor,
which is a secreted protein involved in tumor growth and angiogenesis.
It was previously known that some glioblastoma patients with recurrent
tumors responded well to bevacizumab treatment and experienced longer
progression-free survival and fewer symptoms than most patients with
glioblastoma. This led to a multicenter phase III trial (RTOG-0825) to
evaluate bevacizumab treatment for patients with newly diagnosed
Dr. Sulman and colleagues sought potential molecular markers that would
allow clinicians to identify which patients are most likely to respond
to bevacizumab treatment. The researchers found that tumors with lower
expression of some genes associated with mesenchymal cells responded
better than other tumors to bevacizumab treatment. The researchers then
used this information to create a predictive test for bevacizumab
Dr. Sulman said, “One of the key things about this predictor is that
it’s designed to be used on archival tissue samples, so it doesn’t
require fresh tissue.” This will allow the test to be used widely
because surgical resection is the initial treatment for most patients
with glioblastoma and the tissue obtained is most commonly stored as
The results of the study were presented at the annual meeting of the
American Society of Clinical Oncology in June. In the future, Dr.
Sulman and his colleagues hope to validate their predictive test in
additional glioblastoma patients and assess whether the method is
generalizable to other tumor types. These measures could help identify
patients who will respond well to bevacizumab treatment.
Researchers Identify Potential New Target in EGFR-Activated Cancers
Epidermal growth factor receptor (EGFR), a well-known cancer drug
target, regulates MCM7, a protein vital to the first step in DNA
replication, a team led by researchers at The University of Texas MD
Anderson Cancer Center reported.
MCM7 is important to DNA licensing, the initial step in DNA
replication. MCM7’s function—which is often deregulated in human
cancers—had not previously been tied to EGFR signaling, which leads to
DNA synthesis and cell growth. The researchers found that EGFR
activated MCM7 by activating another signaling molecule, Lyn.
“We established that this signaling pathway correlates with EGFR status
and poor survival in breast cancer patients,” said Mien-Chie Hung,
Ph.D., a professor in and chair of the Department of Molecular and
Cellular Oncology and the study report’s senior author.
The researchers assessed the expression statuses of activated Lyn and
MCM7 in tumor samples from breast cancer patients, and Kaplan-Meier
analyses revealed that the overall survival rates of patients with low
expression of either activated protein were significantly higher than
those of patients with high expression of either activated protein.
Seventy-five months after the completion of their initial therapy,
about 60% of patients with high levels of activated Lyn or MCM7
expression were alive, whereas more than 80% of those with low levels
of activated Lyn or MCM7 expression were alive.
In a mouse model of breast cancer, the researchers found that mice with
high expression of either Lyn or MCM7 had tumor volumes that were two
to three times larger than those of mice with low expression of either
Dr. Hung said, “Lyn overexpression might be indispensable for cancer
cells that rely on EGFR signaling to proliferate,” which suggests that
Lyn is a promising therapeutic target in EGFR-activated cancers. Drugs
that target EGFR often become less effective over time, he noted, so
Lyn provides a potentially effective target downstream from EGFR.
Lyn inhibitors have been tested preclinically and in an early-stage
clinical trial. Combining Lyn and EGFR inhibitors could have a
synergistic effect on EGFR-driven cancers.
The study’s findings were published in the June issue of Cancer Cell.
information, talk to your physician, visit www.mdanderson.org, or call askMDAnderson at 877-632-6789.
articles in OncoLog, August 2013 issue:
Home/Current Issue | Previous Issues
| Articles by
Topic | Patient
About Oncolog | Contact OncoLog | Sign
Up for E-mail Alerts
©2014 The University of
Texas MD Anderson Cancer Center
1515 Holcombe Blvd., Houston, TX 77030
1-877-MDA-6789 (USA) / 1-713-792-3245
Referral Legal Statements Privacy